Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma

• Main Authors: Qian Zhao (Author), Teng Wang (Author), Huanhuan Wang (Author), Cheng Cui (Author), Wen Zhong (Author), Diyi Fu (Author), Wanlin Xi (Author), Lu Si (Author), Jun Guo (Author), Ying Cheng (Author), Hongqi Tian (Author), Pei Hu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Malignant melanoma is an aggressive disease. Tunlametinib (HL-085) is a potent, selective, and orally bioavailable MEK1/2 inhibitor. The objective of this study was to determine the pharmacokinetics (PK) of tunlametinib and its main metabolite M8 in patients with NRAS-mutant melanoma fol...